Skip to content
Katalyze announces $10.5M seed round. Read the press release

Half the time. Half the cost.

About Katalyze

Our ambition is to cut the time and cost of taking a new lifesaving medication to market in half by 2030.

Come Work With Us
The road to 2030

A future where lifesaving medicines arrive sooner.

  1. 2022

    Katalyze is founded

    The Toronto office opens the same year.

  2. 2023

    Sanofi, the first customer

  3. 2024

    San Francisco

    The San Francisco office opens.

  4. 2025

    The AI Biomanufacturing Council

    The Council begins, with scientists and engineers from across pharma.

  5. July 2026

    A $10.5 million seed round

    Led by Bonfire Ventures.

    Read the Announcement
  6. 2026

    New York City

    The New York City office opens.

  7. Today

    40 employees and growing

    5 of the pharma top 20 run Katalyze.

    Come Work With Us
  8. 2030

    The goal

The team

Builders, scientists and creatives.

  • CareersJoin the Team
Offices

San Francisco, Toronto and New York City.

  • San Francisco
  • Toronto
  • New York City
The chemistry laboratory at Howard University, Washington, D.C., about 1900 (Library of Congress)Two technicians at the vaccine bench at the U.S. Public Health Service's Rocky Mountain Laboratory, Hamilton, Montana; one looks up from her work (Library of Congress)
The AI Biomanufacturing Council

Built with the people who make medicine.

More than a hundred scientists and engineers from across pharma, from companies such as Pfizer, Sanofi and Lilly, are helping shape Katalyze, and the future of their own industry with it. They know what it takes to get a medicine to the people who need it. If you do too, come build with us.

Advisors
  • Erik PrieditisErik PrieditisCOO at Sentrex Health Solutions
  • Nicole K. Paulk, PhDNicole K. Paulk, PhDFounder and CEO of Siren Biotechnology
  • Mike TomascoMike TomascoChief Information Officer at Fujifilm
  • Chris CalabrettaChris CalabrettaFormer executive at J&J
  • Shachi SharmaShachi SharmaChief Quality Officer at LabConnect
  • Michael BurtonMichael BurtonFormer Senior Director at Veeva Systems
Investors

Most AI in this category is a thin copilot bolted onto legacy tools. Katalyze went the other way and built real infrastructure. By putting a GxP-native context layer underneath autonomous agents, they let AI reason across the messy, fragmented data of pharma manufacturing and actually do the work: solving deviations faster, improving yield, running critical workflows at a fraction of the cost. That's the unlock the industry has been waiting for, and Reza's team is the one delivering it.

Brett QueenerGeneral Partner at Bonfire Ventures

Backed by Bonfire Ventures, Inovia Capital, Ripple Ventures and Alumni Ventures, with angel investors including Gokul Rajaram and Farzad Soleimani.

Speak with Reza Regarding Investment

For the science. For the people it serves.

More than 10 million doses have made their way to patients around the globe through Katalyze, and counting.

The Katalyze team in the office, around a sign that reads katalyze, agentic infrastructure for life sciences